Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28452075 | 0.89 | SLC6A4 (0.45) | HTR1AHTR3AGAAALDH1A1CYP1A2 | |
| SCHEMBL446449 | 0.87 | AR (0.47) | HTR1AHTR3AGAAALDH1A1 | |
| Benzaldehyde SCHEMBL28454798 | 0.87 | TTR (0.55) | NTRK1IGF1RFGFR1NTRK2GAA | |
| SCHEMBL12195197 | 0.86 | ALDH1A1 (0.58) | HTR1AHTR3AGAAALDH1A1HTT | |
| SCHEMBL24125036 | 0.86 | PAX8 (0.46) | NTRK1IGF1RFGFR1NTRK2HTR1A | |
| SCHEMBL13799708 | 0.85 | TTR (0.47) | GAAALDH1A1LTA4HTSHRHTT | |
| SCHEMBL822665 | 0.83 | TSHR (0.50) | GAAALDH1A1LTA4HTSHRHTT | |
| SCHEMBL30695769 | 0.83 | TSHR (0.50) | GAAALDH1A1LTA4HTSHRHTT | |
| SCHEMBL10602950 | 0.83 | LTA4H (0.50) | NTRK1IGF1RFGFR1NTRK2ALDH1A1 | |
| SCHEMBL12795603 | 0.83 | LTA4H (0.50) | NTRK1IGF1RFGFR1NTRK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814403-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| EP-2871180-B1 | 2-AMINONICOTINIC ACID ESTER DERIVATIVE AND BACTERICIDE CONTAINING SAME AS ACTIVE INGREDIENT | AGRO KANESHO CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-4278816-A | FROM DIPHENYL ETHERS AND HYDROGEN SULFIDE, ABSORPTIVE CATALYST | STAUFFER CHEMICAL COMPANY (US) | 1981-07-14 | — | — | US | disclosed |
| US-3989721-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3989720-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3988352-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-10-26 | — | — | US | disclosed |
| US-3979414-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3965115-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3963753-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3963752-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3951618-A | Method of use of, and compositions containing, disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-04-20 | — | — | US | disclosed |
| US-3949084-A | Novel substituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NTRK1 2208/4885IGF1R 4509/4885FGFR1 3322/4885 |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NTRK1 2208/4885IGF1R 4509/4885FGFR1 3322/4885 |
| US-11814403-B2 | Organic electroluminescent materials and devices | PDCD1, TEC, PDCD4 | NTRK1 2013/4885IGF1R 1290/4885FGFR1 3031/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NTRK1 2208/4885IGF1R 4509/4885FGFR1 3322/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NTRK1 2208/4885IGF1R 4509/4885FGFR1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.